GILEAD SCIENCES INC Form 8-K October 25, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported):	October 23, 2007

Gilead Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-19/31	94-3047598
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
333 Lakeside Drive, Foster City, California		94404
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including	area code:	650-574-3000
	Not Applicable	
Former nar	me or former address, if changed since la	ast report
Check the appropriate box below if the Form 8-K filing he following provisions:	ng is intended to simultaneously satisfy	the filing obligation of the registrant under any of
Written communications pursuant to Rule 425 un Soliciting material pursuant to Rule 14a-12 under Pre-commencement communications pursuant to Pre-commencement communications pursuant to	the Exchange Act (17 CFR 240.14a-12 Rule 14d-2(b) under the Exchange Act () (17 CFR 240.14d-2(b))

Edgar Filing: GILEAD SCIENCES INC - Form 8-K



On October 24, 2007, Gilead Sciences, Inc., a Delaware corporation (the Company), issued a press release announcing the establishment of a stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (the Plan) on October 23, 2007 by Paul Berg, Ph.D., a member of the Company's Board of Directors. Transactions will be executed under the Plan beginning in February 2008. A copy of the press release is filed as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit Number Description
99.1 Press Release, issued by Gilead Sciences, Inc. on October 24, 2007.

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Gilead Sciences, Inc.

October 25, 2007 By: /s/ John F. Milligan, Ph.D.

Name: John F. Milligan, Ph.D.

Title: Chief Operating Officer and Chief Financial Officer

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on October 24, 2007.